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Introduction: Novel coronavirus 2019 (COVID-19) has propagated a global pandemic with significant 
health, economic and social costs. Emerging emergence has suggested that several factors may be 
associated with increased risk from severe outcomes or death from COVID-19. Clinical risk 
prediction tools have significant potential to generate individualised assessment of risk and may be 
useful for population stratification and other use cases. 
 
Methods and analysis: We will use a prospective open cohort study of routinely collected data from 
1205 general practices in England in the QResearch database. The primary outcome is COVID-19 
mortality (in or out-of-hospital) defined as confirmed or suspected COVID-19 mentioned on the death 
certificate, or death occurring in a person with SARS-CoV-2 infection between 24th January and 30th 
April 2020. Our primary outcome in adults is COVID-19 mortality (including out of hospital and in 
hospital deaths). We will also examine COVID-19 hospitalisation in children. Time-to-event models 
will be developed in the training data to derive separate risk equations in adults (19-100 years) for 
males and females for evaluation of risk of each outcome within the 3-month follow-up period (24th 
January to 30th April 2020), accounting for competing risks. Predictors considered will include age, 
sex, ethnicity, deprivation, smoking status, alcohol intake, body mass index, pre-existing medical co-
morbidities, and concurrent medication. Measures of performance (prediction errors, calibration and 
discrimination) will be determined in the test data for men and women separately and by ten-year age 
group. For children, descriptive statistics will be undertaken if there are currently too few serious 
events to allow development of a risk model. The final model will be externally evaluated in (a) 
geographically separate practices and (b) other relevant datasets as they become available.  
 
Ethics and dissemination: The project has ethical approval and the results will be submitted for 
publication in a peer-reviewed journal.  
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Strengths and limitations of the study  
• The individual-level linkage of general practice, Public Health England testing, Hospital 
Episode Statistics and Office of National Statistics death register datasets enable a robust and 
accurate ascertainment of outcomes 
• The models will be trained and evaluated in population-representative datasets of millions of 
individuals 
• Shielding for clinically extremely vulnerable was advised and in place during the study 
period, therefore risk predictions influenced by the presence of some ‘shielding’ conditions 
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The first cases of infection caused by the novel coronavirus SARS-CoV-2 (the virus causing 
coronavirus disease 2019 [COVID-19]) in the UK were confirmed on 24th January 2020 and the first 
UK death on 28th Feb 2020. Since then, the disease has spread rapidly through the population. There 
are currently no licensed vaccines, preventative or curative treatments for COVID-19, although one 
disease modifying treatment has shown promise in terms of reducing time to symptom resolution1. 
Therefore, the UK government has used social (physical) distancing and ‘shielding’ as non-
pharmacological population-level interventions to limit the rate of increase in cases and adverse 
outcomes. 
 
Case series of individuals with confirmed COVID-19 have identified age2, sex3, certain co-
morbidities2,4, excess weight 2 and ethnicity5 as potentially important risk factors for exposure to 
infection, susceptibility to infection, hospitalisation, or death due to infection. As illustrated by a 
recent systematic review6, prediction models for COVID-19 are quickly entering the academic 
literature to support medical decision making at a time when they are urgently needed. Three models 
have been identified that predict hospital admission from pneumonia and other events (as proxy 
outcomes for COVID-19 pneumonia) in the general population. Ten prognostic models for predicting 
mortality risk, progression to severe disease, or length of hospital stay. The systematic review 
indicated that proposed models are poorly reported, with high risk of bias, and their reported 
performance is probably optimistic6.  
 
Current government guidance for COVID-19 identifies individuals based on three broad levels of 
clinical risk (GPs are coding these as low, medium and high risk): 
 
• Clinically Extremely Vulnerable (CEV) group: who are advised to shield (GP code: high risk) 
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• Clinically Vulnerable (CV) group: who are advised to follow stringent social distancing 
measures (GP code: medium risk) 
• The remainder of the population: who are currently following mandatory social distancing 
measures (lockdown followed by gradual easing of measures), but who have not been advised 
to follow specific clinical advice (GP code: low risk). 
 
These policies allow the ability for the National Health Service (NHS), working across government, 
to deliver sustained behavioural and social interventions to protect patients based on clinical need. At 
the heart of these policies is nationwide health data and, in this proposal, we seek to further use NHS 
health data to inform risk stratification. Whilst shielding and stringent social distancing are both 
interventions designed to reduce the risk of exposure to SARS-CoV-2, the classification of risk relates 
to risk of complicated or fatal disease if infected and not the risk of becoming infected. 
 
Clinically Vulnerable (CV): Senior clinicians and expert groups in government initially identified a 
vulnerable group (of around 18 million), broadly identified as the at-risk group for influenza, who 
were eligible for a flu vaccine either on grounds of age (70 and over), pregnancy or comorbidity. 70+ 
was chosen rather than 65+, recognising the sharp rise in representation of the over 70s rather than the 
over 65s in extant hospital case series. There was an estimated 5% reduction in cases and a 15-35% 
reduction in mortality. On 16th March 2020, the UK government recommended that this group follow 
stringent social distancing measures to reduce their risk of contracting the virus.  
 
Clinically Extremely Vulnerable (CEV):  Further clinical consensus emerged that, within the wider 
vulnerable group, a smaller number of individuals with particular conditions might be at much higher 
risk of complicated or fatal disease if infected. Work therefore commenced to identify a much smaller 
clinically extremely vulnerable group (CEV) for inclusion on a Shielded Patient List (SPL) for whom 
advice included staying at home and avoiding all face-to face contact. The SPL is a dynamic list, but 
currently sits at approximately 2.1m individuals, who are entitled to a wider government support 
package. This policy was announced on 22nd March 2020. 
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It should be noted that the advice to the Clinically Vulnerable (CV) group was not mandatory and 
predated wider societal measures brought in with ‘lockdown’, which now essentially sees everybody 
mandated to follow more stringent advice. This has resulted in the above three separate groups: CEV 
(who are advised to shield, also non mandatory), CV (who are advised to follow stringent social 
distancing measures) and the remainder of the population (who are currently following stringent 
social distancing measures due to lockdown, but who have not been advised to follow specific clinical 
advice). 
 
Based on the best available evidence at the time, CEV patients were identified using 4 methodological 
approaches (described as Groups 1-4 in profession-facing communications). This approach was 
mirrored as far as possible by the devolved administrations: 
 
• Method (Group) 1: Identification of a core group of CEV patients who have been identified in 
England by NHS Digital and contacted centrally by NHSE. This group comprised 6 
categories of conditions.  
• Method (Group) 2: Identification of people in particular medical subspecialties in secondary 
care not identifiable centrally. 
• Method (Group) 3: Identification of additional CEV patients by secondary care specialists 
using clinical judgement. 
• Method (Group) 4: Identification of a small number of CEV patients in primary care using 
clinical judgement. 
 
The original SPL was intended to identify people with particular conditions which put them at highest 
clinical risk of severe morbidity or mortality from COVID-19, based on our understanding of the 
disease at the time.  It was developed early in the outbreak when there were very little data or 
evidence about the groups most at risk of poor COVID-19 outcomes, and so was intended to be a 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted June 29, 2020. ; https://doi.org/10.1101/2020.06.28.20141986doi: medRxiv preprint 
 8
dynamic list that would adapt as our knowledge of the disease improved and more evidence became 
apparent. 
 
Given the emerging evidence on risk factors for COVID-19, and as lockdown is eased, the 
government is reviewing the evidence on which the initial decision to stratify patients by risk into 
vulnerability groups was based.  This is especially relevant given that age, sex, BMI, ethnicity and 
certain co-morbidities are now emerging as signals for poor clinical outcomes. 
 
As a result, England’s Chief Medical Officer asked NERVTAG to convene this expert subgroup to 
consider the data and evidence for risk factors for severe COVID-19 outcomes and death, and assess 
whether a predictive risk algorithm can be developed with the above evidence to permit a more 
sophisticated  ‘risk stratification’ approach. There are a variety of potential uses for such a tool, but it 
is primarily anticipated that it could be used both clinically in informing patients of their individual 
risk category and managing them accordingly, and strategically to stratify the population for policy 
purposes. 
 
The use of primary care datasets with contemporaneous linkage to relevant registries such as death 
records, hospital admissions data and COVID-19 testing results represents a novel approach to 
clinical risk prediction modelling for COVID-19 as they provide accurately coded, individual-level 
data for large numbers of a representative national population. This scenario predicates rich 
phenotyping of individuals with regards to a multitude of demographic, medical, pharmacological and 
other candidate predictors across various aspects of the health system for the purposes of robust 
statistical modelling, and the unparalleled sample size facilitates rigorous evaluation of any derived 
models. Such linked datasets have an established track record for the development, evaluation and 
transparent reporting of clinical risk models for conditions including (but not limited to) 
cardiovascular disease, diabetes and cancers 7-11. Therefore, the biases and limitations identified in 
extant risk models relevant to COVID-19 may be ameliorated by such an approach.  
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Any risk stratification model will need to be kept under regular review to evaluate performance and 
will need updating as data and disease epidemiology evolve.  
Objectives and Use Cases 
 
In this study, we will describe the development and evaluation of novel COVID-19 risk prediction 
equations and corresponding tools for initial use in the NHS that will also be available internationally, 
subject to external evaluation per individual geography. It is anticipated that the equations will be 
widely available for use and that the equations will be updated regularly as understanding of COVID-
19 increases, as more and better data become available, and as underlying susceptibility/immunity or 
policy/behaviour in the population changes or the virus itself mutates. It is also important to recognise 
at the outset that there will be limitations to any model that is produced and that the use of the model 
should be reviewed and updated regularly to ensure it remains fit for purpose. 
 
It is also important to emphasise that this study will produce an estimated risk of both catching the 
virus and subsequently being seriously harmed – it will need to be further adapted to produce a risk of 
harm, given infection. 
 
It is important for the population, patients, staff and the NHS that there is one widely used and 
appropriately developed tool which is consistently implemented across the service and which is 
supported by the academic, NHS and patient communities. This will then help ensure consistent 
policy and clear national communication between policy makers, professionals and the public. 
 
There are numerous use cases which need to be articulated which will affect the design of the tool, but 
once developed, the algorithm can be adapted and developed a semi-automated fashion.   
 
The risk algorithms can be used in various ways (examples below are based on the various ways 
which www.qrisk.org has been implemented and used across the NHS over the last 12 years). 
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• Within a consultation between the patient and a clinician (either in primary care, or the 111 
service) with the intention of sharing the information with the patient to assess management 
options.  
 
o For example, a 54-year old Indian man with diabetes wishes to know his risk of 
serious COVID-19 in order to take action to reduce his exposure to being infected. 
This could be achieved through development of a risk calculator for use within a 
consultation. 
 
• To electronically risk-stratify populations to appropriately target clinical or non-
pharmacological interventions towards different groups of patients based on levels of risk.  
 
o For example, a GP practice needs to identify patients to recommend shielding, to 
prioritise for preventative therapies (such as weight management) or vaccination 
(when available). This could be achieved through the implementation of the risk 
equations via software embedded in GP clinical computer systems. This will ensure 
the tool can be applied to up-to-date electronic health records for direct clinical care 
purposes. It is not intended that this tool is used to make treatment decisions 
following admission to hospital however, since it will be developed using a general 
primary care population and different clinical variables will need to be considered at 
hospital admission. Furthermore, it does not aim to predict the expected outcomes of 
patients under different treatments. 
 
• To inform mathematical modelling of the potential impact of interventions or changes in 
policy (e.g. shielding, prioritisation for vaccination, occupational health, health economic 
analyses).  
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o For example, national and local governments need to assess the impact of changing 
guidelines on the risk categories or thresholds  e.g. how many patients would be 
reclassified as high/medium/low risk and what the resource implications would be. 
 
• Adapted for use by the general public to improve communication and understanding of risk 
through implementation into web-based tools: this would require additional segmentation in 
identifying, say, ‘very low risk’ populations 
 
o For example, a school or community needs to highlight predictors of adverse 
outcomes and link to recommendations in behaviours in particular to individuals at 
high risk to help reduce transmission of COVID-19, or individual members of the 
public to be better informed about the risks of different groups.  
 
• To inform a personalised discussion between an employee and their employer regarding their 
occupational duties. 
 
o For example, key workers, health or care workers at high risk may wish to discuss 
working in a setting or role that has a lower risk of encountering patients with 
COVID-19 infection.  
 
• Use by researchers to help generate new knowledge or insights.  
 
o For example, a risk stratification tool could be used to identify high risk patients to be 
invited to join a clinical trial or to adjust an analysis for baseline predictors of the 
outcome. 
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The initial prediction tool is being developed for public health purposes rather than for individual 




Study design and data source 
 
We will undertake a cohort study in a large population of primary care patients using the QResearch® 
database (version 44). We will include all practices in England who had been using their EMIS 
computer system for at least a year. We will randomly allocate three quarters of QResearch practices 
to the training dataset and the remaining quarter to a test dataset. We will further evaluate the derived 
model using a dataset derived from data from GP practices using a different clinical system, ideally 
with a different geographical distribution from QResearch since this provides a stronger test of 
external validity.  Further evaluations will be undertaken in external datasets to assess the models in 
more diverse settings. For example, we will seek to validate the algorithm using other datasets in 
Wales and Scotland.  
Data sources 
QResearch-Linked database: 
QResearch is a high-quality research database established in 2002 which has been used extensively 
for the development of risk prediction tools which are widely used across the NHS7-11 as well as a 
wide range of high impact epidemiological research12. QResearch is a large, representative, validated 
GP practice research database nationally13. Until April 2020, there were 1205 practices contributing, 
covering a population of 10.5 million patients. Following a recruitment invitation, the database has 
now doubled to 2519 practices in England, 193 in Northern Ireland and 3 in Scotland which will 
cover approximately 21 million current patients. There are currently no practices in Wales. 
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The QResearch database is linked at an individual patient level to hospital admissions data (including 
intensive care unit data), COVID-19 RT-PCR positive test results held by Public Health England, the 
national shielded patient list held by NHS Digital, cancer registrations (including radiotherapy and 
systemic chemotherapy records) and mortality records obtained from the Office for National 
Statistics. The records are linked using a project-specific pseudonymised NHS number. The recording 
of NHS numbers is valid and complete for 99.8% of QResearch patients, 99.9% for ONS mortality 
records and 98% for hospital admissions records14,15.  
 
Two new data linkages could be undertaken if available and information governance (IG) approved, 
linked to NHS numbers, which could then be pseudonymised using OpenPseudonymiser 
(www.openpseduonymiser.org) to assess: 
 
1. Register of health care workers 
2. The COVID-19 Clinical Information Network (CO-CIN) database on >40,000 patients 
hospitalised with COVID-19.   
 
If these linkages were undertaken, the research objectives would be expanded to specifically examine 
the risks for health care workers which could directly inform policy regarding the creation of the 
shielded list and also quantify the risks experienced by health care workers to inform occupational 
health considerations. 
 
English Datasets – OpenSAFELY 
OpenSAFELY is a new secure analytics platform for electronic health records in the NHS, created to 
deliver urgent results during the global COVID-19 emergency. It is based on TPP SystmOne software 
from over 2000 general practices using TPP SystmOne software. It currently covers a population of 
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24 million patients’ full pseudonymised primary care NHS records. It is linked to records of hospital 
death from COVID-19, ITU data, and ONS death data including cause of death. 
Scottish datasets – MRC funded EAVE II dataset 
We will validate our risk score using the EAVE II (Early Assessment of COVID-19 epidemiology and 
Vaccine/anti-viral Effectiveness dataset. This project was triggered and expanded (with funding from 
the MRC), to pivot an NIHR-funded Pandemic Influenza Preparedness study (EAVE) to COVID-19.  
EAVE II has created a national electronic cohort though linking health data sets from general practice, 
prescribing, ICU, A&E, hospitalisations and virology testing using the unique Community Health 
Identification (CHI) number for residents of Scotland. EAVE II has collected electronic data from at 
least 5.3m individuals living in Scotland to study COVID-19. 
 
Welsh datasets – SAIL 
In Wales, the Secure Anonymised Information Linkage (SAIL) Databank, holds anonymised data 
from multiple health and non-health systems16. In response to the COVID-19 crisis, a complete 
population cohort (3.2m people) is being created, linking demographic, mortality, hospital, general 
practice, community prescribing, virus sequencing, COVID-19 test results and multiple other datasets 
to track the progress of the epidemic and evaluate the effectiveness of counter measures.   
 
Study population 
We will identify open cohorts of individuals registered with practices (that have been contributing to 
QResearch for over 12 months) on or after 24th January 2020. We will exclude patients 
(approximately 0.1%) who do not have a valid NHS number. Patients will enter the cohort on 24th 
January 2020 which is approximately five weeks prior to the first recorded COVID-19 death in the 
UK on 28th February. The administrative censoring date is the date of most recent data for each 
outcome. The date of the outcome of interest will be observed for patients having the outcome. 
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Patients who are not observed to have the outcome of interest in the will be censored at the 
administrative censoring date. 
 
Outcomes 
For participants aged 19-100 
Our primary outcome is COVID-19 mortality (including out of hospital and in hospital deaths) 
defined as confirmed or suspected COVID-19 as mentioned on the death certificate (ICD-10 codes 
U071 & UO72), or death occurring in a patient with a SARS-COV-2 confirmed infection in the period 
from 24th January (date of first confirmed COVID-19 case in UK) to the last date up to which death 
data are available. Our secondary outcome is hospital admission in a patient with a SARS-COV-2 
confirmed infection 
For participants aged 0-18 
 
For those aged under 19 years, our primary outcome is hospital admission in a patient with a SARS-
COV-2 confirmed infection. Our secondary outcome is a composite measure including either COVID-
19 mortality (as defined above) OR hospital admission SARS-COV-2 confirmed infection. 
 
Candidate predictor variables  
We will examine the following candidate predictor variables based on risk factors already identified 
in national guidance as defining or being associated with membership of clinically extremely 
vulnerable and clinically vulnerable groups; those already used in widely used risk equations14 (since 
these can be implemented rapidly); and variables highlighted in the related literature9,11,17-20. Currently 
(June 2020), the SPL 4 stage method allows additional patients to be added by their clinician in 
primary or secondary care. 9,11,17-20  The predictor list will be amended by future updates as new 
knowledge on emerging risk factors becomes available.  
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For analyses in people aged 0 to 18 years, we will identify predictor variables applicable to children. 
However, initial analyses show there are currently too few events to develop a separate risk calculator 
children so exploratory, descriptive analyses will be undertaken. Similarly, the analyses of pregnancy 
will also be considered separately. 
Demographic variables 
1. Age (continuous variable) 
2. Townsend deprivation score. This is an area-level continuous score based on the patients’ 
postcode21. Originally developed by Townsend21, it includes unemployment (as a 
percentage of those aged 16 and over who are economically active); non-car ownership 
(as a percentage of all households); non-home ownership (as a percentage of all 
households) and household overcrowding. These variables are measured for a given area 
of approximately 120 households, via the 2011 census, and combined to give a 
“Townsend score” for that area. A greater Townsend score implies a greater level of 
deprivation. 
3. Ethnicity (9 categories) 
4. Lives in a care home (nursing home or residential care) 
5. Homelessness 
Lifestyle factors 
6. Smoking status (non-smoker, ex-smoker, light, moderate, heavy) 
7. Body mass index (continuous variable; in children, z-scores will be used) 
8. Crack Cocaine and Injecting Drug Use 
9. Alcohol dependence 
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Current shielded list (https://digital.nhs.uk/coronavirus/shielded-patient-list#risk-criteria) 
10. Solid organ transplant recipients who remain on long term immune suppression therapy 
11. Cancer 
a. people with cancer who are undergoing active chemotherapy 
b. people with cancer who are undergoing radical radiotherapy for lung cancer 
c. people with cancers of the blood or bone marrow such as leukaemia, lymphoma or 
myeloma who are at any stage of treatment 
d. people having immunotherapy or other continuing antibody treatments for cancer * 
e. people having other targeted cancer treatments which can affect the immune system, 
such as protein kinase inhibitors or PARP inhibitors * 
f. People who have had bone marrow or stem cell transplants in the last 6 months, or 
who are still taking immunosuppression drugs 
12. People on immunosuppression therapies sufficient to significantly increase risk of 
infection 
13. People with severe respiratory disease22 
a. Severe asthma – prescribed 3 or more prescriptions of steroids over the previous 12 
months  
b. Severe chronic obstructive pulmonary disease (COPD) prescribed 3 or more 
prescriptions of steroids over the previous 12 months 
c. Cystic fibrosis or Interstitial Lung Disease or Sarcoidosis or non-CF bronchiectasis or 
pulmonary hypertension 
14. People with rare diseases and inborn errors of metabolism that significantly increase risk 
of infection, such as severe combined immunodeficiency (SCID) or homozygous sickle 
cell 
15. People who are pregnant with significant heart disease, congenital or acquired 
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Moderate risk of developing complications from coronavirus (COVID-19) infection (categories as per 
current NHS guidance) 
16. Chronic respiratory disease (non-severe) 
a. Asthma 
b. COPD (emphysema and chronic bronchitis) 
c. Extrinsic allergic alveolitis  
17. Chronic kidney disease  
a. CKD stage 3 or 4 
b. End-stage renal failure requiring dialysis 
18. Heart disease  
a. Congestive cardiac failure  
b. Valvular heart disease 
19. Chronic liver disease  
a. Chronic infective hepatitis (hepatitis B or C infection) 
b. Alcohol-related liver disease 
c. Primary biliary cirrhosis 
d. Primary sclerosing cholangitis  
e. Haemochromatosis  
20. Chronic neurological conditions 
a. Epilepsy  
b. Parkinson’s disease  
c. Motor neurone disease  
d. Multiple sclerosis  
e. Cerebral palsy   
g. Dementia - Alzheimer's, vascular dementia, frontotemporal dementia  
h. Down syndrome 
21. Diabetes mellitus 
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a. Type 1 diabetes 
b. Type 2 diabetes  
22. Conditions or treatments predisposing to infection (including steroids) 
a. Rheumatoid arthritis  
b. Systemic lupus erythematosus  
c. Ankylosing spondylitis or other inflammatory arthropathy such as psoriatic arthritis   
d. Connective tissue disease (Ehlers-Danlos, scleroderma, Sjögren’s syndrome) 
e. Polymyositis  
f. Dermatomyositis  
g. Vasculitis – giant cell arteritis, polyarteritis nodosa, polymyalgia rheumatica, 
Behçet’s syndrome, microscopic polyangitis  
 
Other medical conditions that we hypothesise may confer elevated risk: 
23. Cardiovascular disease 
a. Atrial fibrillation 
b. Cardiovascular events (Heart attack, angina, stroke or TIA) 
c. Peripheral vascular disease 
d. Treated hypertension (hypertension and current antihypertensive treatment) 
24. Hyperthyroidism 
25. Chronic pancreatitis 
26. Cirrhosis if not included (see above) 
a. Including non-alcoholic steatohepatitis/fatty liver disease 
27. Malabsorption 
a. Coeliac disease 
b. Steatorrhea 
c. Blind loop syndrome 
28. Peptic ulcer (gastric or duodenal ulcer, simple or complicated ulcer) 
29. Learning disability 
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30. Osteoporosis (clinical diagnosis of osteoporosis or on DEXA scan) 
31. Fragility fracture (hip, spine, shoulder or wrist fracture) 
32. Severe mental illness 
a. Bipolar affective disorder  
b. Psychosis  




36. Sickle cell disease  
37. Tay-Sachs and other sphingolipidoses 
38. History of venous thromboembolism 
39. Tuberculosis 
Concurrent medication 
40. Drugs affecting the immune response including systemic chemotherapy based on hospital 
data 
41. Drugs affecting the immune response prescribed in primary care focusing on BNF chapter 
8.2. 
42. Long acting beta agonist (LABA) 
43. Long acting muscarinic agonist (LAMA) 
44. Inhaled corticosteroids (ICS) 
 
All predictor variables will be based on the latest coded information recorded in the GP record prior to 
entry to the cohort.  
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Development of the models  
We will use the following steps: 
1. Development of prognostic models for each outcome within the training data 
2. Evaluation of predictive performance in the test data 
3. Fitting the final model in the complete cohort and presentation of the final model 
 
Separate models will be developed and evaluated for males and females aged 19-100 and aged <19. 
 
Development of the models using the training data 
For all analyses, the time origin is 24th January 2020 and the risk period of interest is from 24th 
January up to the last date at which death data (for primary outcome in adults) or hospital admissions 
data are available. For the composite outcome of hospitalisation or death the risk period for the 
analysis is up to the minimum date at which death and hospital admission data are available. We will 
develop and validate evaluate the risk prediction equations using established methods8,23-26   
 
The outcomes of interest are subject to competing risks. For the primary outcome of COVID-19 
death, the competing risk is death due to other cases. For the secondary outcome of hospitalisation, 
the competing risk is death from any cause prior to hospitalisation. We will deal with competing risks 
in two ways.  
 
First, we will use cause-specific Cox proportional hazards models for each outcome. Second, we will 
fit a single sub-distribution hazard (Fine and Gray) model for each outcome. Therefore, three cause-
specific hazard models are fitted and three sub-distribution hazard models. All models are fitted 
separately in men and women. For the cause-specific hazard models, individuals are censored at the 
time at which a competing event occurs, for the sub-distribution hazard model individuals who did not 
have the outcome of interest are censored at the study end date including those who had a competing 
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event. We will use second degree fractional polynomials (i.e. with up to two powers)31 to model non-
linear relationships for continuous variables (age, body mass index and Townsend score). Separate 
fractional polynomial terms will be modelled for participants aged 0-19 years (when included, i.e. for 
the risk of hospitalisation models). Models will include interactions between BMI and ethnicity and 
interactions between predictor variables and age focussing on predictor variables which apply across 
the age range (asthma, epilepsy, diabetes, severe mental illness) where numbers allow.  
Handling of missing data 
For all predictor variables, we will use the most recently available value at the time origin (24th 
January 2020). For indicators of co-morbidities and medication use, the absence of information being 
recorded is assumed to mean absence of the factor in question. There may be missing data in four 
variables due to never being recorded: ethnicity, Townsend score, body mass index and smoking 
status. We will use multiple imputation with chained equations to replace missing values for these 
variables 27-30. Prior to the imputation, a complete-case analysis will be fitted using a model containing 
only the continuous covariates within the training data to derive the fractional polynomial order and 
corresponding powers. For computational efficiency, we will use a combined imputation model for 
the three outcomes. 31 The imputation model will be fitted in the training data and will include all 
predictor variables along with age interaction terms, the interaction between BMI and ethnicity, the 
Nelson–Aalen estimators of the baseline cumulative hazard, and the outcome indicators (namely, 
death from COVID, other deaths, and hospitalisation). Separate imputation models will be fitted for 
men and women separately. We will carry out 5 imputations as this has a relatively high efficiency29 
and is a pragmatic approach accounting for the size of the datasets and capacity of the available 
servers and software.  
 
Each analysis model will be fitted in each imputed data set. In the outcome models BMI is modelled 
using fractional polynomial terms and there are interactions between BMI and ethnicity, and BMI and 
age. A passive imputation approach will be used, with the imputed BMI value being transformed 
using the fractional polynomial function derived in the complete case analysis and being used in the 
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interaction term. We will use Rubin’s rules to combine the model parameter estimates and the 





We will fit models that include all predictor variables initially. If some predictor variables result in 
very sparse cells (i.e. with not enough participants or events to obtain point estimates and standard 
errors), we will combine some of these if clinically similar in nature. In addition, if variable selection 
is deemed necessary (e.g. is there is evidence of overfitting, such as very large estimated coefficients, 
or if the rich model cannot be fitted [does not converge] or the model performance is very poor), we 
will use penalised logistic models (specifically, LASSO) on the binary mortality outcome to screen 
(select) the variables (with the optimal penalty chosen via 5-fold cross-validation [CV]). It 
recommended that for best practice, well-established predictors and those with clinical credibility will 
be included and retained in the model. Currently, COVID-19 is a new disease and knowledge 
regarding which variables are established predictors is still accruing, therefore the clinical team 
members agreed a list of variables that should be included based on emerging evidence in the 
literature and public health recommendations that have been made. These clinically relevant predictor 
variables will then be retained in the LASSO models. Interaction terms will be considered as new 
variables. The variables with non-zero coefficients and the pre-specified relevant predictors will be 
included in the prediction models. This will be done on the complete cases (after standardising 
continuous variables and creating indicator variables for each category for categorical ones), and use 
the selected variables in the imputation models, and then the final model. In the event that logistic 
lasso with 5-fold CV proves too computationally intensive, and thus infeasible, we will do the 
variable selection on a subsample of the total data. The subsample will be a case-cohort sample, 
including all cases (for the outcome in question) plus a stratified random sample of the whole training 
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data cohort (including the cases), with stratification by sex and age group, representing 10% of the 
training data.   The selected model is then fitted in the complete training data.  
 
Risk equations 
We will then combine the regression coefficients for each variable from the final models with an 
estimate of the baseline survivor function or baseline cumulative incidence to derive risk equations 
(cumulative incidence equations) for each outcome, with risk pertaining to the period from 24th 
January to the latest date at which death or hospital admission data were available39. This will be done 
separately using the cause-specific hazard analyses and the sub-distribution hazard analyses. For the 
cause-specific hazard analyses the risk for a given outcome depends on the cause-specific hazard 
models for all competing causes and we will use a published formula34 to derive the cumulative 
incidence function in this case. 33 33 33 33 31 29 32 32 32 32 33 
 
Evaluation of the models 
In the test data, we will fit an imputation model to enable imputation of missing values for ethnicity, 
body mass index and smoking status. The imputation model will exclude the outcome indicator and 
Nelson-Aalen terms, as the aim is to use the covariate data to obtain a prediction as if the outcome had 
not been observed. We will carry out 5 imputations. We will apply the risk equations for males and 
females obtained from the training data to the test data and calculate measures of performance.  
 
As in previous studies34, we will calculate R2 values (explained variation where higher values indicate 
a greater proportion of variation in survival time explained by the model 35), Brier score as a measure 
of predictive performance, D statistics36 (a measure of discrimination which quantifies the separation 
in survival between patients with different levels of predicted risk where higher values indicate better 
discrimination) and Harrell’s C statistics at 4 months and combine these across datasets using Rubin’s 
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rules. Harrell’s C statistic37 is a measure of discrimination (separation) which quantifies the extent to 
which those with earlier events have higher risk scores. Higher values of Harrell’s C indicate better 
performance of the model for predicting the relevant outcome. A value of 1 indicates that the model 
has perfect discrimination. A value of 0.5 indicates that the model discrimination is no better than 
chance. We will use adequate modifications of Brier and C-index for competing risk models.  
  
We will calculate 95% confidence intervals for the performance statistics to allow comparisons with 
alternative models for the same outcome and across different subgroups. 38 
 
We will assess calibration of the risk scores by comparing the mean predicted risks evaluated at 4 
months with the observed risks by tenth of predicted risk. The observed risks will be obtained using 
nonparametric estimates of the cumulative incidences, obtained for men and women (and separately 
for adults/people aged<20 years).  
 
We will also evaluate these performance measures in 6 pre-specified age groups (20-39;40-49; 50-59; 
60-69; 70-79; 80+), 9 ethnic groups; individual disease conditions (e.g. diabetes), and within each of 
the 10 English regions. 
 
The final model 
The evaluation above is conducted separately using the two approaches (cause-specific hazards and 
sub-distribution hazard models). The approach resulting in the best predictive performance, as judged 
through consideration of the measures and assessments outlined above, will be taken forward as the 
final model. We seek a model with high discrimination, low Brier score and good calibration. The 
imputation model fitted in the test data (excluding the outcome) is first refitted in the full data. The 
final outcome model is fitted in each imputed data set using the full data and estimates combined 
using Rubin’s Rules.  
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Updating of the model using new data 
We will update the models when the data are updated to cover a longer period. The baseline survivor 
function is likely to change after significant policy changes, so will be updated in future models to 
account for this where possible32. Even though it may not be possible to fully account for changes in 
baseline survival over time the risk scores will give a rank ordering of patients that can be used for 
risk stratification/identification of high-risk groups. 
 
 
Exploratory analyses  
In addition, we will undertake a set of exploratory analyses after the aforementioned models are fitted. 
Given that the data used to derive the main models were generated during a time when shielding was 
in place, there may be underestimation of the predictive weights of some ‘shielded’ conditions, as we 
were unable to observe the ‘full potential risk’ of these diseases. To examine this further, we will use 
a stratified Cox model approach. Here, we will stratify the population on the basis of shielding status 
(a binary measure), thus allowing the baseline hazard to vary in the two sub-groups of the study 
cohort. When obtaining predictions for the shielded population, we will use the baseline hazard for the 
non-shielded sub-cohort. Another exploratory analysis may include fitting the model in different time 
periods – such as in the time between first positive cases and 2 weeks after the date on which 
individuals were first advised to shield/were added to the shielded patient list. We would also fit the 
model during the time period where shielding occurred and compare model performance.  
 
Development of risk categories 
Since there is no currently accepted threshold for classifying high risk of COVID-19 outcomes, we 
will examine the distribution of predicted risks and calculate a series of centile values. For each 
centile threshold, we will calculate the sensitivity, specificity, positive and negative predictive values 
of the risk scores over a 4-month follow-up. A range of possible categorisations will also be explored 
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corresponding to different levels of risk, based on the risk score derived from the log-hazard ratios 
(coefficients) of the primary Cox regression model.   
 
We will use all the relevant patients on the database to maximise the power and generalisability of the 
results. We will use Stata (version 16) and R statistical software for analyses. We will adhere to the 
TRIPOD statement for reporting39. 
 
Patient and public involvement 
Patients and members of the public will be involved in setting the research question, the outcome 
measures, the design, implementation and dissemination of the study findings. A multi-ethnic panel of 
patient representatives will also advise on dissemination including the use of culturally appropriate lay 
summaries describing the research and its results. 
 
Implementation 
A web-based program will implement the risk-stratification procedure. In a similar manner for 
QRISK, a range of alternative communication formats are possible and will be empirically evaluated. 
These could include a full risk-score, a risk-categorisation, alternative representations of relative and 
absolute risk for the appropriate risk-category, or translation into a ‘COVID-age’. Multiple versions of 
the tool will be available to allow the user to directly enter information (for example, via an “app”) as 
well as versions which allow pre-population of exiting data via electronic health care record systems. 
In all implementations it will be made clear that the risks being communicated are not ‘your’ risks: 
they are essentially what we have observed based on medical records in a group of initially uninfected 
people.  
 
The prediction model is for the combined risk of infection and then death (or hospitalisation). 
Therefore, it will be important to emphasise that the model is a prediction model and is not a causal 
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model, and as such the model parameters do not have a causal interpretation. Despite this, there may 
be potential risks regarding misinterpretation of the results of our work. As such, we will work 
towards clear and robust communication of this in any clinical or public-facing tools, including but 
not limited to any publications that result from this work.  
 
NHS Digital will ensure that implementations meet medical device regulations requirements. For 
transparency and to ensure wide availability of the resulting tools, all code underlying the 
implementation will be published as open source software and freely available.  
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Discussion of methodology and approach 
Ethical considerations 
We see an important distinction between (a) factors which are included in a risk equation to ensure 
that the risk estimates are as accurate as possible and (b) how the risk equation is then used in 
guidelines and clinical practice to ensure ethical, effective, and equitable access to services for 
everyone.   
 
The primary purpose of our study is to report on the development and validation of new risk equations 
rather than to produce national policy or clinical guidance although we recognise the results may be 
used by policy makers and clinicians. All clinical decisions regarding the beneficial and safe use of 
these risk equations necessarily remain the responsibility of the attending health care professional. 
This initial tool is being developed for public health purposes rather than for individual therapeutic or 
health care decisions, except for interventions aimed at prevention of infection.  
 
There are, however, ethical issues to consider regarding how the tools may be used. We have analysed 
this within the “four ethical principles” framework which is widely used in medical decision making. 
The four principles are autonomy, beneficence, justice and non-maleficence40. The new risk 
equations, when implemented in clinical software, are designed to provide more accurate information 
for patients and clinicians on which to base decisions thereby promoting shared decision making and 
patient autonomy. They are intended to result in clinical benefit by identifying where changes in 
management are likely to benefit patients, thereby promoting the principle of beneficence. Justice can 
be achieved by ensuring that the use of the risk equations results in fair and equitable access to health 
services which is commensurate with the patients’ level of risk. Lastly the risk assessment must not be 
used in a way which causes harm either to the individual patient or to others (for example, by 
introducing or withdrawing treatments where this is not in the patients’ best interest) thereby 
supporting the non-maleficence principle. How this applies in clinical practice will naturally depend 
on many factors especially the patient’s wishes, the evidence based for any interventions, the 
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clinician’s experience, national priorities and the available resources. The risk assessment equations 
therefore supplement clinical decision making not replace it. 
 
As this work is conducted, we must be aware that as COVID-19 is a poorly understood disease in 
terms of its clinical behaviour and risks, the outputs may contain results that seem to be counter-
intuitive, or go against what we understand for other diseases. Should this occur, we will rigorously 
explain that any new observations in this project cannot be interpreted as being causal and should not 
form the basis for any change in behaviour or trigger any intervention. If novel insights or 
counterintuitive results are obtained, these will be explored further in other studies, as this does not 
fall under the remit of our aim to produce a prediction tool. 
  
Comparison with other risk scores 
A recent systematic review by Wynants et al6, et al. identified 27 studies reporting 31 multivariable 
risk prediction models pertaining to either the prediction of hospital admission for COVID pneumonia 
(actual or presumed, n=3), diagnostic models for detecting infection (n=18), or prognostic models in 
confirmed cases (n=10). Their review also covered non-peer reviewed manuscripts submitted on open 
access pre-print repositories.  
 
Whilst all included studies were identified as being at high risk of bias (as per PROBAST), and very 
few offered meaningful indication of the details of their construction or intended use, they offer a 
reference point for the status and quality of risk prediction modelling in this pandemic. Interestingly, 
the review did not identify any models that predicted risk of death in the general population as our 
study intends to do as its primary outcome of interest, the prognostic models instead estimated 
mortality risk in those with suspected or confirmed COVID infection (n=6), risk of prolonged hospital 
stay (n=2), or progression to severe disease/a critical state (n=2).  
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Regarding our secondary endpoint of interest (risk of hospitalisation due to COVID-19), three models 
were identified by Wynants, et al6. aiming to predict risk of hospital admission at a general population 
level. However, none of these models were developed using a dataset that contained any COVID-19 
cases, instead using admission for a suite of respiratory infections as proxy events.  
 
In contrast to these models that have a high risk of bias, non-representative samples and imperfectly 
described methodology, our study cohort covers a significant proportion of the United Kingdom and 
is population-representative, has the advantage of accurate ascertainment of myriad predictors and 
outcomes, and we will adhere to consensus reporting guidelines (TRIPOD).   
 
Strengths  
The methods to derive and validate these models are broadly the same as for a range of other widely 
used clinical risk prediction tools derived from the QResearch database 7-11. The strengths and 
limitations of the approach have already been discussed in detail 8,11,23,24,41,42. In summary, key 
strengths include size, wealth of data on risk factors, good ascertainment of outcomes through 
multiple record linkage, prospective recording of outcomes, use of an established validated database 
which has been used to develop many risk prediction tools, and lack of selection, recall and 
respondent bias and robust analysis. UK general practices have good levels of accuracy and 
completeness in recording clinical diagnoses and prescribed medications 43. We think our study has 
good face validity since it has been conducted in the setting where most patients in the UK are 
assessed, treated and followed up.  
 
Limitations 
Limitations of our study include the lack of formal adjudication of diagnoses, potential for 
misclassification of outcomes depending on testing, information bias, and potential for bias due to 
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missing data. Our database has linked mortality and hospital admissions data and is therefore likely to 
have picked up the great majority of COVID-19 related ICU admissions and death thereby 
minimising ascertainment bias. The initial evaluation will be done on a separate set of practices and 
individuals to those which were used to develop the score although the practices all use the same GP 
clinical computer system (EMIS – the computer system used by 55% of UK GPs). An independent 
evaluation will be a more stringent test and should be done (e.g. using data from different clinical 
systems or the other countries within the UK), but when such independent studies have examined 
other risk equations, 41,42,44,45 they have demonstrated similar performance compared with the 
validation in the QResearch database7,8,23.  Whilst our study population is from England and is 
representative of the English population, we will need to evaluate its performance in other datasets 
which are representative of the other devolved nations.  We are however validating the risk score 
using both the EAVE II national cohort which includes data on over 90% of the Scottish population. 
A particular limitation in the COVID-19 context is that much of the outcome data will have been 
generated whilst social distancing and other public health measures have been in place, and therefore 
may not be fully representative of risk in the absence of these measures. 
 
For transparency, we will publish the model itself and source code for the equations on a publicly 
available website with an appropriate license (e.g. LGPL). The rationale for this is to ensure that those 
interested in reviewing or using the open source will then be able to find the latest available version as 




We will develop a set of new equations to quantify risk of adverse COVID-19 outcomes, taking 
account of demographic, social and clinical variables. The equations are intended to provide a valid 
measure of those outcomes the general population of patients tested in separate validation cohort. The 
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equations can be used in conjunction clinical guidelines to enable patients to be identified for focused 
assessments and interventions.  
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